Suppr超能文献

住院新发失代偿期肝硬化患者的出院结局。

Discharge Outcomes of Hospitalized Patients with New Onset Decompensated Cirrhosis.

机构信息

Department of Medicine, Lewis Katz School of Medicine, Temple University, 3401 N Broad ST, Philadelphia, PA, USA.

出版信息

Dig Dis Sci. 2024 Sep;69(9):3220-3225. doi: 10.1007/s10620-024-08574-8. Epub 2024 Jul 31.

Abstract

INTRODUCTION

There are a lack of data describing outcomes and follow-up after hospital discharge for patients with newly diagnosed cirrhosis with complication on index admission. This study examines factors that influence outcomes such as readmission, follow-up, and mortality for patients with newly diagnosed cirrhosis.

METHODS

We conducted a single-center retrospective chart review study of 230 patients with newly diagnosed cirrhosis from January 1st, 2020 through December 31st, 2021. We obtained demographics, clinical diagnoses, admission, and discharge MELD-Na, disposition, mortality, appointment requests rate, appointment show rate, and readmission.

RESULTS

The primary complications on admission were GI bleed (27%), ascites (25.7%), and hepatic encephalopathy (HE) (10.4%). Overall, the median length of stay (LOS) was 6 days, and the readmission rate was 27%. Out of 230 patients, 25 (10.9%) patients died while hospitalized while another 43 (18.6%) died after initial discharge within the two-year study period. Although there was a significant reduction of the MELD-Na from admission to discharge (p < 0.05), admission MELD-Na did not correlate with LOS and discharge MELD-Na did not predict readmission. Patients with HE had the highest median LOS, while patients with ascites had the highest readmission rate. The median time to an appointment was 32 days. When comparing discharge destinations, most patients were discharged to home (63%), to facilities (13.9%), or expired (10.9%). The average appointment show rate was 38.5%, although 70% of patients had appointment requests. Readmission rate and mortality did not differ based on appointment requests. No significant differences in outcomes were observed based on race, sex, or insurance status.

CONCLUSION

New diagnosis of decompensated was found to have high mortality and high readmission rates. Higher MELD-Na score was seen in patients who died within 30 days. Routine appointment requests did not significantly improve readmission, mortality, increase appointment show rate, or decrease time to appointment. A comprehensive and specialized hepatology-specific program may have great benefits after cirrhotic decompensation, especially for those with newly diagnosed cirrhosis.

摘要

简介

目前缺乏关于索引入院时伴有并发症的新诊断肝硬化患者出院后结局和随访的数据。本研究旨在探讨影响新诊断肝硬化患者结局的因素,如再入院、随访和死亡率。

方法

我们对 2020 年 1 月 1 日至 2021 年 12 月 31 日期间在单中心接受治疗的 230 例新诊断肝硬化患者进行了回顾性图表审查研究。我们获得了患者的人口统计学、临床诊断、入院和出院时的 MELD-Na、处置、死亡率、预约请求率、预约就诊率和再入院率等数据。

结果

入院时的主要并发症为胃肠道出血(27%)、腹水(25.7%)和肝性脑病(10.4%)。总体而言,中位住院时间(LOS)为 6 天,再入院率为 27%。230 例患者中,25 例(10.9%)在住院期间死亡,另有 43 例(18.6%)在两年研究期间初次出院后死亡。尽管入院时 MELD-Na 与出院时相比显著降低(p<0.05),但入院时 MELD-Na 与 LOS 无关,出院时 MELD-Na 也不能预测再入院。有肝性脑病的患者 LOS 最长,而有腹水的患者再入院率最高。预约时间中位数为 32 天。比较出院去向,大多数患者出院回家(63%)、去机构(13.9%)或死亡(10.9%)。平均预约就诊率为 38.5%,尽管 70%的患者有预约请求。再入院率和死亡率与预约请求无关。基于种族、性别或保险状况,未观察到结局的显著差异。

结论

新诊断的失代偿性肝硬化患者死亡率和再入院率均较高。30 天内死亡的患者 MELD-Na 评分较高。常规预约请求并未显著降低再入院率、死亡率、提高预约就诊率或缩短预约时间。在肝硬化失代偿后,全面的、专业化的肝脏病学治疗方案可能具有显著的益处,特别是对于新诊断的肝硬化患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d00f/11415393/7a31cbec00e0/10620_2024_8574_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验